Alliance Oncology’s acquisition of US Radiosurgery will expand the scope of operations handled by the Nashville company.
Alliance announced its $54 million purchase of US Radiosurgery on Tuesday. Under the deal, Alliance will shift the management of its steretotactic radiosurgery centers to US Radiosurgery, which will continue its operations in Nashville and retain its brand as a division of Alliance. George Stevens, CEO of US Radiosurgery, said the deal “almost doubles” the number of centers it’s supporting and gives the company a strong development base.
“At this time we have our largest pipeline in the history of the company,” Stevens said.
Pharmaceutical companies can then concentrate development resources on drugs that are most active against tumor cells, and can also identify which patients might respond best to the experimental chemotherapy agents in clinical trials. Because of this unique capability the MiCK assay can be a valuable tool in the field of Drug Discovery by reducing the costs associated with validation studies and the time required to obtain FDA approval for marketing.For more on DiaTech, click here.
- ALEX B FRUIN INHERITANCE TRUST; CANDACE F STEFANSIC INHERITANCE TRUST; CANDANCE F STEFANSIC INHERITANCE TRUST; FRUIN, ALEX B TRUSTEE; FRUIN ALEX B INHERITANCE TRUST; STEFANSIC, CANDACE F TRUSTEE; STEFANSIC CANDACE F INHERITANCE TRUST; STEFANSIC CANDANCE F INHERITANCE TRUST
- ROSS, BRIDGETT D
- COOKE, ETHEN LANYARD TRUSTEE; COOKE, ETHEN LEWIS ESTATE
- JACOBS, JESSICA ALEXANDRA; JACOBS, ERIKA BESS